Table 1 Baseline Characteristics of the cohort population

Number

119

95

24

Demographics

 Age, years

71 (10)

71 (11)

70 (6)

0.578

 Female, N (%)

45 (38)

40 (42)

5 (21)

0.092

Cancer Types, N (%)

0.065

 NSCLC

29 (24)

24 (25)

5 (21)

 Melanoma

19 (16)

17 (18)

2 (8)

 Renal Cell Carcinoma

27 (23)

21 (22)

6 (25)

 Hepatocellular Carcinoma

23 (19)

17 (18)

6 (25)

 Breast

6 (5)

2 (2)

4 (17)

 Cervical Squamous

6 (5)

6 (6)

0 (0)

 Other

9 (8)

8 (8)

1 (4)

Cancer Stages N (%)

0.851

 2

1 (1)

1 (1)

0 (0)

 3

13 (11)

10 (11)

3 (12)

 4

105 (88)

84 (88)

21 (88)

Metastasis N (%)

105 (93)

83 (93)

22 (92)

1.000

Brain metastasis N (%)

0.507

 No

31 (27)

23 (26)

8 (33)

 Yes

11 (10)

10 (11)

1 (4)

 Unknown

71 (63)

56 (63)

15 (63)

Bone metastasis N (%)

0.159

 No

64 (57)

52 (59)

12 (50)

 Yes

41 (37)

29 (33)

12 (50)

 Unknown

7 (6)

7 (8)

0 (0)

Lung metastasis N (%)

0.360

 No

49 (44)

38 (43)

11 (48)

 Yes

48 (43)

37 (42)

11 (4)

 Unknown

15 (13)

14 (16)

1 (4)

Liver metastasis N (%)

0.358

 No

60 (53)

46 (52)

14 (58)

 Yes

46 (41)

36 (40)

10 (42)

 Unknown

7 (6)

7 (8)

0 (0)

Lymph node metastasis N (%)

0.189

 No

33 (30)

25 (28)

8 (33)

 Yes

68 (61)

52 (59)

16 (67)

 Unknown

11 (10)

11 (13)

0 (0)

ECOG N (%)

0.094

 0

36 (41)

24 (34)

12 (71)

 1

39 (44)

35 (49)

4 (4)

 2

9 (10)

8 (11)

1 (6)

 3

3 (3)

3 (4)

0 (0)

Immunotherapy Type N (%)

0.441

 Pembrolizumab

28 (24)

24 (25)

4 (17)

 Nivolumab

10 (8)

8 (8)

2 (8)

 Avelumab

9 (8)

8 (8)

1 (4)

 Atezolizumab

36 (30)

25 (26)

11 (46)

 Ipilimumab + Nivolumab

36 (30)

30 (32)

6 (25)

Previous ICIs N (%)

4 (3)

3 (3)

1 (4)

0.713

Number of ICIs cycles, median [IQR]

6 [3, 17]

5 [3, 17]

8 [4, 14]

0.261

Number of ICIs lines, median [IQR]

1 [1, 2]

1 [1, 2]

1 [1, 1]]

0.201

Line of treatment N (%)

0.319

 1

72 (65)

55 (63)

17 (71)

 2

31 (28)

26 (30)

5 (21)

 3

6 (5)

5 (6)

1 (4)

 4

1 (1)

1 (1)

0 (0)

 5

1 (1)

0 (0)

1 (4)

Previous lines, median [IQR]

0 [0,1]

0 [0, 1]

0 [0,0]

0.595

 0

87 (73)

67 (71)

20 (83)

 1

21 (18)

19 (20)

2 (8)

 2

6 (5)

5 (5)

1 (4)

 3

3 (3)

2 (2)

1 (4)

 4

2 (2)

2 (2)

0 (0)

Chemotherapy/Biological plus ICIs N (%)

39 (33)

23 (24)

16 (67)

 < 0.001

Only ICIs, N (%)

80 (67)

72 (76)

8 (33)

Chemo plus ICIs, N (%)

24 (20)

13 (14)

11 (46)

Biological plus ICIs, N (%)

15 (13)

10 (11)

5 (21)

Cardio-Vascular Risk Factors

 Hypertension, N (%)

70 (59)

56 (59)

14 (58)

1.000

 Smoking, N (%)

9 (8)

7 (7)

2 (8)

1.000

 Ischemic Heart Disease, N (%)

26 (22)

16 (17)

10 (42)

0.019

 Obstructive Sleep Apnea, N (%)

1 (1)

1 (1)

0 (0)

1.000

 BMI baseline, mean (SD)

28.6 (5.5)

28.7 (5.7)

28.3 (4.8)

0.708

 Hyperlipidemia, N (%)

41 (34)

29 (31)

12 (50)

0.120

 Chronic Kidney Disease, N (%)

8 (7)

6 (6)

2 (8)

1.000

Cardiovascular Medications, N (%)

 MRA

11 (9)

6 (6)

5 (21)

0.072

 ARNI

4 (3)

2 (2)

2 (8)

0.380

 ACEI

41 (34)

30 (32)

11 (46)

0.283

 ARB

35 (29)

26 (27)

9 (38)

0.470

 Statin

82 (69)

60 (63)

22 (92)

0.014

 Furosemide

17 (14)

12 (13)

5 (21)

0.484

 Beta blocker

58 (49)

43 (47)

15 (62)

0.200

 Metformin

91 (76)

71 (75)

20 (83)

0.375

 GLP-1

1 (1)

1 (1)

0 (0)

1.000

Baseline Laboratory Parameters

 HbA1C %, median [IQR]

6.6 [6.1, 7.3]

6.6 [6.0, 6.9]

7.1 [6.3, 8.3]

0.089

 WBC K/Ul, mean (SD)

9.4 (3.4)

9.5 (3.5)

9.2 (3.0)

0.756

 Platelet K/Ul, mean (SD)

240.2 (83.7)

243.8 (85.1)

225.6 (77.6)

0.352

 Hematocrit %, mean (SD)

33.6 (6.2)

32.8 (6.0)

37.0 (6.1)

0.003

 Creatinine mg/Dl, median (IQR)

0.9 [0.7, 1.2]

0.9 [0.7, 1.2]

1.0 [0.9, 1.2]

0.351

 Troponin I ng/L baseline, median (IQR)

5.5 [2.5, 14.2]

6.0 [4.0, 15.0]

3.0 [0.5, 7.5]

0.056

 Troponin I ng/L following ICIs, median (IQR)

8.0 [5.0, 23.0]

8.0 [5.0, 23.5]

8.0 [5.0, 21.0]

0.762